Literature DB >> 27240263

Autoimmune polyglandular syndrome type 3 (APS-3) among patients with premature ovarian insufficiency (POI).

Katarzyna Szlendak-Sauer1, Daniel Jakubik1, Michał Kunicki2, Jolanta Skórska1, Roman Smolarczyk1.   

Abstract

OBJECTIVES: Autoimmune polyglandular syndrome type 3 - (APS-3), is defined as the coexistence of autoimmune thyroiditis with other non-ovarian autoimmune diseases without primary adrenal insufficiency. Additionally the definition of APS-3 also includes primary ovarian insufficiency (POI) coexistence with autoimmune thyroiditis. The main goal of that study is to assess the prevalence of APS-3 defined as coexistence of autoimmune thyroiditis with POI in population of 46 XX karyotype women with primary ovarian insufficiency (POI). The second goal is to investigate hormonal profile and insulin sensitivity in women with POI and subgroups of women with APS-3 - POI/APS-3(+) and without APS 3 - POI/APS-3(-).
MATERIALS AND METHODS: Anthropometric measurements, coexistence of autoimmune diseases, androgens, fasting glucose and insulin, glucose and insulin at 60' and 120' of oral glucose tolerance test (OGTT) and homeostasis model for insulin resistance (HOMA-IR), were determine in 98 patients aged between 18 and 39 with spontaneous 46 XX primary ovarian insufficiency (POI), in 33 POI/APS-3(+), 65 POI/APS-3(-), and 75 healthy controls.
RESULTS: Continuous data were summarized by the mean±standard deviation (SD), and categorical data by number (percentages). Data were checked for normality using Shapiro-Wilk test, the comparison between groups were performed using non-parametric Mann-Whitney or Kruskall-Wallis test. Pearson's correlation coefficient was used to assess the relationships between parameters. Statistical significance was defined as p values <0.05. Autoimmune thyroid disease (ATD) was presented in 33/98 (33.7%) patients with POI. The groups did not differ significantly in respect to age and body mass index (BMI). Women with POI, POI/APS-3(+) and POI/APS-3(-) showed significantly lower serum androgens in comparison to controls. Additionally women with POI/APS-3(+) showed hyperinsulinemia after 1h of OGTT; No significant differences in serum fasting glucose, insulin and during 2h OGTT between groups were observed.
CONCLUSIONS: The prevalence of APS-3 is 33.7% in patients with spontaneous 46 XX primary ovarian insufficiency. Women with POI, POI/APS-3(+) and POI/APS-3(-) feature lower testosterone, androstendione, dehydroepiandrostendione sulphate in comparison to controls. Women with POI/APS-3(+) could have hyperinsulinemia and should be carefully evaluated for metabolic disorders.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmune polyglandular syndrome (APS); Autoimmune thyroid disease (ATD); Hashimoto's thyroiditis; Premature ovarian failure (POF); Premature ovarian insufficiency (POI)

Mesh:

Substances:

Year:  2016        PMID: 27240263     DOI: 10.1016/j.ejogrb.2016.05.023

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  4 in total

1.  Does the Value of FSH Predict Severity of Metabolic Complications in Females with POI?

Authors:  Michał Kunicki; Jagoda Kruszewska; Jolanta Skórska; Hanna Laudy-Wiaderny; Marcin Wrona; Roman Smolarczyk
Journal:  J Clin Med       Date:  2022-04-05       Impact factor: 4.241

Review 2.  Metabolic differences in women with premature ovarian insufficiency: a systematic review and meta-analysis.

Authors:  Wang-Yu Cai; Xi Luo; Wei Wu; Jianyuan Song; Ning-Ning Xie; Cuicui Duan; Xiao-Ke Wu; Jian Xu
Journal:  J Ovarian Res       Date:  2022-09-30       Impact factor: 5.506

3.  Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis.

Authors:  Midhun Soman; Li-Cong Huang; Wen-Hui Cai; Jun-Bi Xu; Jun-Yao Chen; Ren-Ke He; Heng-Chao Ruan; Xiang-Rong Xu; Zhi-Da Qian; Xiao-Ming Zhu
Journal:  Menopause       Date:  2019-01       Impact factor: 2.953

Review 4.  Autoimmune Diseases in Patients with Premature Ovarian Insufficiency-Our Current State of Knowledge.

Authors:  Anna Szeliga; Anna Calik-Ksepka; Marzena Maciejewska-Jeske; Monika Grymowicz; Katarzyna Smolarczyk; Anna Kostrzak; Roman Smolarczyk; Ewa Rudnicka; Blazej Meczekalski
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.